Epigallocatechin gallate inhibits human tongue carcinoma cells via HK2-mediated glycolysis

Oncology Reports

Volumn 33, Issue 3, 2015, Pages 1533-1539

  Gao, Feng ^a   Li, Ming ^b   Liu, Wen Bin ^b   Zhou, Zhong Su ^b   Zhang, Rui ^b   Li, Jun Ling ^a   Zhou, Ke Chao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Central South University   (China)

Author keywords

Akt; EGCG; HK2; Tongue carcinoma

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIGALLOCATECHIN GALLATE; HEXOKINASE; HEXOKINASE 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CATECHIN; EGFR PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE;

ANCHORAGE INDEPENDENT GROWTH; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EXPOSURE; GLYCOLYSIS; HUMAN; HUMAN CELL; METABOLIC REGULATION; MITOCHONDRIAL MEMBRANE; OUTER MEMBRANE; TONGUE CARCINOMA; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; CHEMOPROPHYLAXIS; DRUG EFFECTS; ENZYME ACTIVATION; METABOLISM; PHYSIOLOGY; TONGUE NEOPLASMS; TUMOR CELL LINE;

ANTICARCINOGENIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CATECHIN; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOPREVENTION; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GLYCOLYSIS; HEXOKINASE; HUMANS; MITOCHONDRIAL MEMBRANES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; TONGUE NEOPLASMS;

EID: 84921652886     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3727     Document Type: Article

References (48)

1. Dreosti IE, Wargovich MJ and Yang CS: Inhibition of carcinogenesis by tea: the evidence from experimental studies. Crit Rev Food Sci Nutr 37:761-770, 1997.
2. Katiyar S and Mukhtar H: Tea in chemoprevention of cancer. Int J Oncol 8:221-238, 1996.
3. Yang CS, Maliakal P and Meng X: Inhibition of carcinogenesis by tea. Annu Rev Pharmacol Toxicol 42:25-54, 2002.
4. Katiyar SK and Elmets CA: Green tea polyphenolic antioxidants and skin photoprotection (Review). Int J Oncol 18:1307-1313, 2001.
5. Yang CS: Inhibition of carcinogenesis by tea. Nature 389:134-135, 1997.
6. Yang CS and Wang H: Mechanistic issues concerning cancer prevention by tea catechins. Mol Nutr Food Res 55:819-831, 2011.
7. Ma YC, Li C, Gao F, et al: Epigallocatechin gallate inhibits the growth of human lung cancer by directly targeting the EGFR signaling pathway. Oncol Rep 31:1343-1349, 2014.
8. Maruyama T, Murata S, Nakayama K, et al: (-)-Epigallocatechin-3-gallate suppresses liver metastasis of human colorectal cancer. Oncol Rep 31:625-633, 2014.
9. Bode AM and Dong Z: Epigallocatechin 3-gallate and green tea catechins: united they work, divided they fail. Cancer Prev Res 2:514-517, 2009.
10. Shirakami Y, Shimizu M and Moriwaki H: Cancer chemoprevention with green tea catechins: from bench to bed. Curr Drug Targets 13:1842-1857, 2012.
11. Singh BN, Shankar S and Srivastava RK: Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol 82:1807-1821, 2011.
12. Shimizu M, Shirakami Y and Moriwaki H: Targeting receptor tyrosine kinases for chemoprevention by green tea catechin, EGCG. Int J Mol Sci 9:1034-1049, 2008.
13. Khoi PN, Park JS, Kim JH, et al: (-)-Epigallocatechin-3-gallate blocks nicotine-induced matrix metalloproteinase-9 expressionand invasiveness via suppression of NF-κBand AP-1 in endothelial cells. Int J Oncol 43:868-876, 2013.
14. Dong Z, Ma W, Huang C and Yang CS: Inhibition of tumor promoter-induced activator protein 1 activation and cell transformation by tea polyphenols, (-)-epigallocatechin gallate, and theaflavins. Cancer Res 57:4414-4419, 1997.
15. Rouzer CA and Marnett LJ: Green tea gets molecular. Cancer Prev Res 4:1343-1345, 2011.
16. Bode AM and Dong Z: Targeting signal transduction pathways by chemopreventive agents. Mutat Res 555:33-51, 2004.
17. Jankun J, Selman SH, Swiercz R and Skrzypczak-Jankun E: Why drinking green tea could prevent cancer. Nature 387:561, 1997.
18. He Z, Tang F, Ermakova S, et al: Fyn is a novel target of (-)-epigallocatechin gallate in the inhibition of JB6 Cl41 cell transformation. Mol Carcinog 47:172-183, 2008.
19. Sakamoto Y, Terashita N, Muraguchi T, Fukusato T and Kubota S: Effects of epigallocatechin-3-gallate (EGCG) on A549 lung cancer tumor growth and angiogenesis. Biosci Biotechnol Biochem 77:1799-1803, 2013.
20. Katiyar S, Elmets CA and Katiyar SK: Green tea and skin cancer: photoimmunology, angiogenesis and DNA repair. J Nutr Biochem 18:287-296, 2007.
21. Scully C and Bagan J: Oral squamous cell carcinoma overview. Oral Oncol 45:301-308, 2009.
22. Shah JP and Gil Z: Current concepts in management of oral cancer - surgery. Oral Oncol 45:394-401, 2009.
23. Calabrese L, Tagliabue M, Maffini F, Massaro MA and Santoro L: From wide excision to a compartmental approach in tongue tumors: what is going on? Curr Opin Otolaryngol Head Neck Surg 21:112-117, 2013.
24. Yuen A P, Lam KY, Chan AC, et al: Clinicopathological analysis of elective neck dissection for N0 neck of early oral tongue carcinoma. Am J Surg 177:90-92, 1999.
25. Rana M, Iqbal A, Warraich R, Ruecker M, Eckardt AM and Gellrich NC: Modern surgical management of tongue carcinoma - a clinical retrospective research over a 12 years period. Head Neck Oncol 3:43, 2011.
26. Petersen PE: Global policy for improvement of oral health in the 21st century - implications to oral health research of World Health Assembly 2007, World Health Organization. Community Dent Oral Epidemiol 37:1-8, 2009.
27. Preis M, Hadar T, Soudry E, et al: Early tongue carcinoma: analysis of failure. Head Neck 34:418-421, 2012.
28. Koppenol WH, Bounds PL and Dang CV: Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 11:325-337, 2011.
29. Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell 144:646-674, 2011.
30. Tennant DA, Durán RV and Gottlieb E: Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 10:267-277, 2010.
31. Denko NC: Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 8:705-713, 2008.
32. Wallace DC: Mitochondria and cancer: Warburg addressed. Cold Spring Harb Symp Quant Biol 70:363-374, 2005.
33. Ros S and Schulze A: Glycolysis back in the limelight: systemic targeting of HK2 blocks tumor growth. Cancer Discov 3:1105-1107, 2013.
34. Patra KC, Wang Q, Bhaskar PT, et al: Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell 24:213-228, 2 013.
35. Wolf A, Agnihotri S, Micallef J, et al: Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med 208:313-326, 2011.
36. Yecies JL and Manning BD: Transcriptional control of cellular metabolism by mTOR signaling. Cancer Res 71:2815-2820, 2011.
37. Fruman DA and Rommel C: PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 13:140-156, 2014.
38. Ribeiro FA, Noguti J, Oshima CT and Ribeiro DA: Effective targeting of the epidermal growth factor receptor (EGFR) for treating oral cancer: a promising approach. Anticancer Res 34:1547-1552, 2014.
39. Cheung EC, Ludwig RL and Vousden KH: Mitochondrial localization of TIGAR under hypoxia stimulates HK2 and lowers ROS and cell death. Proc Natl Acad Sci USA 109:20491-20496, 2012.
40. Pastorino JG, Shulga N and Hoek JB: Mitochondrial binding of hexokinase II inhibits Bax-induced cytochrome c release and apoptosis. J Biol Chem 277:7610-7618, 2002.
41. Majewski N, Nogueira V, Bhaskar P, et al: Hexokinasemitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol Cell 16:819-830, 2004.
42. Krasnov GS, Dmitriev AA, Lakunina VA, Kirpiy AA and Kudryavtseva AV: Targeting VDAC-bound hexokinase II: a promising approach for concomitant anti-cancer therapy. Expert Opin Ther Targets 17:1221-1233, 2013.
43. Elattar TM and Virji AS: Effect of tea polyphenols on growth of oral squamous carcinoma cells in vitro. Anticancer Res 20:3459-3465, 2000.
44. Moreira L, Araújo I, Costa T, et al: Quercetin and epigallocatechin gallate inhibit glucose uptake and metabolism by breast cancer cells by an estrogen receptor-independent mechanism. Exp Cell Res 319:1784-1795, 2013.
45. Ueda M, Nishiumi S, Nagayasu H, Fukuda I, Yoshida K and Ashida H: Epigallocatechin gallate promotes GLUT4 translocation in skeletal muscle. Biochem Biophys Res Commun 377:286-290, 2008.
46. Ku HC, Tsuei YW, Kao CC, et al: Green tea (-)-epigallocatechin gallate suppresses IGF-I and IGF-II stimulation of 3T3-L1 adipocyte glucose uptake via the glucose transporter 4, but not glucose transporter 1 pathway. Gen Comp Endocrinol 199:46-55, 2014.
47. Naftalin RJ, Afzal I, Cunningham P, et al: Interactions of androgens, green tea catechins and the antiandrogen futamide with the external glucose-binding site of the human erythrocyte glucose transporter GLUT1. Br J Pharmacol 140:487-499, 2003.
48. Ongkeko WM, Altuna X, Weisman RA and Wang-Rodriguez J: Expression of protein tyrosine kinases in head and neck squamous cell carcinomas. Am J Clin Pathol 124:71-76, 2005.